Oncolytics Biotech Study REMAINS Blinded and 1 Stock that Has Hit 52-Week Lows
Oncolytics Biotech (NASDAQ:ONCY) conducted an internal analysis of the blinded combined clinical data for all patients who were enrolled in the initial stage of the study. The study continues to be blinded, and during the analysis, 23 put of all 80 patients had not progressed but were included for the analysis. The median evolving progression free survival of all 80 patients was larger than initially expected since this was the best response rate. It has been observed that patients for whom only metastatic disease was being measured by clinicians, had a different response to treatment than the patients who suffered from local regional head and neck disease. Patients in whom only metastatic disease was measured saw a median evolving PFS of 120 days, statistically much greater than patients with a noted local regional head and neck tumor. The shares closed at $2.48, down $0.34 or 12.06% on the day. They have traded in a 52-week range of $2.50 to $5.86.
Don’t Miss: INTRODUCING: The iPhone 5.
Pmfg (NASDAQ:PMFG) predicts that its Process Products segment will drive its FY13 revenue growth. The shares closed at $6.86, down $1.21 or 14.99% on the day. They have traded in a 52-week range of $6.90 to $27.40.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>